Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: Incidence, clinicopathological characteristics and prognostic factors

Leukemia and Lymphoma

Volumn 54, Issue 11, 2013, Pages 2433-2440

  Dierickx, Daan ^a   Tousseyn, Thomas ^a,b   Sagaert, Xavier ^a,b   Fieuws, Steffen ^b   Wlodarska, Iwona ^b   Morscio, Julie ^b   Brepoels, Lieselot ^a   Kuypers, Dirk ^a   Vanhaecke, Johan ^a   Nevens, Frederik ^a   Verleden, Geert ^a   Van Damme Lombaerts, Rita ^a   Renard, Marleen ^a   Pirenne, Jacques ^a   De Wolf Peeters, Christiane ^b   Verhoef, Gregor ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Immunosuppression; Posttransplant lymphoproliferative disorder; PTLD; Transplant

Indexed keywords

ANTIVIRUS AGENT; RITUXIMAB; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER PROGNOSIS; CHILD; CLINICAL FEATURE; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART GRAFT; HEMATOPOIETIC STEM CELL; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877288283     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.780655     Document Type: Article

References (32)

1. Swerdlow SH, Webber SA, Chadburn A, et al. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp. 343-349.
2. Tsao L, His ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007;131: 1209-1218.
3. DiNardo CE, Tsai DE. Treatment advances in posttransplant lymphoproliferative disease. Curr Opin Hematol 2010; 17:368-374.
4. Jam A, Nalesnik M, Reyes J, et al. Posttransplant lymphoproliferative disorders in liver transplantation: A 20-year experience. Ann Surg 2002;236:429-436.
5. A predictive model for aggressive non-Hodgkin?s lymphoma: The International Non-Hodgkin?s lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
6. SauerbreiW, SchumacherM. Bootstrap and crossvalidationto access complexity of data-driven regression models. In: Brause RW, Hanisch, E, editors. ISMDA ?00 Proceedings of the First International Symposium on Medical Data Analysis. London: Springer-Verlag; 2000. pp.234-241.
7. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease:Outcomes and prognostic factors in the modern era. J din Oncol 2010;28:1038-1046.
8. Trappe R, Zimmermann H, Fink 5, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphicB-cellpost- transplantlymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: A prospective analysis of 8 cases. Haematologica 201 1;96:1067-1071.
9. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: Issues in prespective. Transplantation 2011;91: 1057-1064.
10. Landgren 0, Gilbert ES, Rizzo DJ, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009;113:4992-5001.
11. Quinlan SC, Pfeiffer RM, Morton LM, et al. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. AmJ Hematol 2011;86:206-209.
12. Thorley-Lawson DA, GrossA. Persistence of the Epstein-Barrvirus and the origins of associated lymphomas. N Engl J Med 2004;350:1328-1337.
13. Kuppers R. B cells under influence:Transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801-812.
14. Mortin LM, Landgren 0, Chatterjee N, et al. Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. Blood 2007;110:4599-4605.
15. Mattila PS, Aalto SM, Heikkilä L, et al. Malignancies after heart transplantation: Presence of Epstein-Barr virus and cytomegalovirus. Clin Transplant 2001;15:337-342.
16. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antib odyrituximab in patientswith post-transplantlymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901-2906.
17. Blaes AH, Peterson BA, Bartlett N, et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: Results of a phase 11 trial. Cancer 2005;104: 1661-1667.
18. Choquet 5, Leblond V Herbrecht R, et al. Efficacy and safety of rituximab in B-Cell post-transplantion lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006;107: 3053-3057.
19. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase 11 trial of extended treatment with rituximab in patients with B-Cell post-transplant lymphoproliferative disease. Haematologica 2007;92:1489-1494.
20. Choquet 5, Oertel 5, LeblondV, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution. Ann Hematol 2007;86:599-607.
21. Trappe R, Oertel 5, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-Cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206.
22. Reshef R, Vardhanabhuti 5, Luskin MR, et al. Reduction of immunosuppression as initial therapy for p osttransplantation lymphoproliferative disorder. Am J Transplant 2001;11:336-347.
23. Swinnen U, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008;86:215-222.
24. Lee JJ, Lam MS, RosenbergA. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Ann Pharmacother 2007;41:1648-1659.
25. Leblond V Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J din Oncol 2001;19:772-778.
26. Ghobrial TM, Habermann TH, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005;23:7574-7582.
27. Hourigan MJ, Doecke J, Mollee PN, et al. A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. Br J Haematol 2008;141:904-907.
28. Dharnidharka VR, Tejanj AH, Ho PL, et al. Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant 2002;2:993-998.
29. R11hijarvi 5, Taskinen M, Jerkeman M, et al. Male gender is an adverse prognostic factor in B-Cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 2001;86:124-128.
30. CoiffierB, OsmanovEA, HongX, etal. Bortezomib plusrituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma:A randomized phase 3 trial. Lancet Oncol 2011; 12:773-784.
31. Gartner B, Preiksaitis JK. EBV viral load detection in clinical virology. J ClinVirol2OlO;48:82-90.
32. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010;23:350-366.